The DCAF6 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population derived from the Raji human B lymphoblast cell line, engineered to disrupt the DCAF6 gene (Homo sapiens). This polyclonal knockout product provides a heterogeneous pool of cells with targeted genetic ablation, enabling functional studies of DCAF6 in a lymphoid context without the constraints of clonal selection. The knockout model is designed for researchers investigating substrate-specific ubiquitination processes and their roles in hematological malignancies.
The Raji host cell line is an Epstein-Barr virus (EBV)-positive Burkitt’s lymphoma-derived model that grows in suspension culture and secretes immunoglobulins. As a B lymphoblast line, Raji cells are widely employed in studies of antibody production, antigen presentation, and B-cell malignancies. Their transformed phenotype and well-characterized signaling pathways make them a powerful system for dissecting oncogenic mechanisms and evaluating therapeutic targets in lymphoma.
DCAF6 functions as a substrate recognition receptor for the CUL4-DDB1-RBX1 E3 ubiquitin ligase (CRL4) complex. It directly interacts with DDB1 and CUL4A or CUL4B, assembling with RBX1 and COP9 signalosome subunits to regulate ubiquitin transfer. Activated by DNA damage signals and ATR/ATM kinase signaling, DCAF6 directs the ubiquitination and subsequent 26S proteasome-dependent degradation of downstream targets, including cell cycle regulators and DNA repair factors. This positions DCAF6 as a critical modulator of genomic stability, linking DNA damage checkpoint control with cell cycle progression.
In the Raji cell background, DCAF6 knockout provides a relevant model for exploring the intersection of ubiquitin-mediated proteolysis and B-cell lymphoma biology. Disruption of DCAF6 may alter the degradation of substrates involved in DNA repair and proliferation, potentially affecting lymphomagenesis and drug sensitivity. The immunoglobulin-producing nature of Raji cells further allows investigation of how CRL4 ligase activity influences B-cell effector functions and malignant transformation, offering insights into molecular vulnerabilities in hematological cancers.
This polyclonal knockout cell pool is applicable to a range of experimental strategies, including functional dissection of the CRL4 ubiquitin ligase complex, analysis of DNA repair pathways, and drug target validation in lymphoma. Researchers can perform Western blotting for protein ubiquitination and turnover, flow cytometry for cell cycle and apoptosis profiling, co-immunoprecipitation of DCAF6-interacting complexes, DNA damage reporter assays, RNA-seq-based gene expression profiling, and drug sensitivity screening. These applications facilitate the identification of synthetic lethal interactions and biomarkers. For further information, please contact Ascent Research.
